Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SpectRx/Abbott Labs

This article was originally published in The Gray Sheet

Executive Summary

Sale of an additional $2.5 mil. in convertible redeemable preferred stock to Abbott completes the purchase of a total of $5.3 mil. in convertible redeemable preferred stock as part of an agreement to jointly develop a continuous glucose monitor. An initial sale of $2.8 mil. in stock was announced late last year (1"The Gray Sheet" Dec. 20, p. 17)

You may also be interested in...



SpectRx/Abbott Labs

Sale of $2.8 mil. in SpectRx convertible redeemable preferred stock to Abbott is included in a joint pact to develop a continuous glucose monitor. An additional $2.5 mil. investment is anticipated Jan. 3. Expanding on an existing alliance between the firms, the revised agreement gives Abbott exclusive worldwide marketing rights to continuous monitoring as well as single-use monitoring applications of the SpectRx technology, which incorporates sensors worn on top of the skin to analyze glucose levels in interstitial fluid (1"The Gray Sheet" June 28, p. 19)

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel